TY - JOUR T1 - Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2022-005065 VL - 10 IS - 7 SP - e005065 AU - Tianyu Tang AU - Xing Huang AU - Gang Zhang AU - Tingbo Liang Y1 - 2022/07/01 UR - http://jitc.bmj.com/content/10/7/e005065.abstract N2 - Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy. ER -